Quest Diagnostics Inc vs Tyson Foods, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.82 (market cap $25.48B), while Tyson Foods, Inc. trades at $52.71 (market cap $18.41B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Tyson Foods, Inc. pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Tyson Foods, Inc. for 76 Days on average.
| DGX | TSN | |
|---|---|---|
Market Cap | $25.48B | $18.41B |
Volume | 941,866 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $68.75 |
52-Week Low | $173.49 | $50.47 |
Typical Hold Time | 56 Days | 76 Days |
Enterprise Value | $31.23B | $25.68B |
Dividend Yield | 1.49% | 3.9% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Tyson Foods (TSN) trades at $51.70, down 0.52% with mixed technical signals showing neutral overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, while Q4 2025 missed. Revenue grew to $54.44B in 2025 with thin 1.03% net margins. Analyst consensus is bullish with 53% buy ratings and $65.40 price target, though recent news highlights challenges in the beef segment and ongoing securities investigations.
The stock presents a value opportunity with low P/S (0.33) and reasonable EV/EBITDA (9.83), but faces significant execution risks from beef segment losses and margin pressure. Upside depends on successful business turnaround and resolution of legal concerns, while current price near 52-week lows offers potential for recovery if fundamentals improve.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →